Maas BiolAB brings Hawaii to Swedish Biomedical Forum

Business Editors and Health/Medical Writers

HONOLULU--(BW HealthWire)--Nov. 1, 1999--Maas BiolAB LLC was chosen to represent Hawaii at the first "CONNECT Sweden BioMedical Partnership Forum" in Goteborg on 1-2 November 1999. The CONNECT Forum offers selected, primarily Scandinavian, emerging innovative biomedical companies to present their technology to international and Scandinavian pharmaceutical and biomedical companies, including Pharmacia-Upjohn, Astra-Zeneca, NeuroSearch, and venture capital firms.

The CONNECT Forum is held north of the Scandinavian "Medicon Valley" called Oresund. It was dubbed Medicon Valley when its universities spawned many innovative biotechnology corporations. Oresund is the name of the narrow body of water between Denmark and Sweden separating the Universities of Copenhagen and Lund.

Maas BiolAB, LLC is a privately held biotechnology company incorporated in Hawaii in 1997. It is a member of the Hawaii Technology Trade Association. Maas BiolAB, LLC holds patents for the use of cyclosporin, the original neuroimmunophilin, to treat acute neurological diseases including stroke, brain trauma, spinal cord injury and status epilepticus as well as chronic neurodegenerative diseases including Alzheimer's, Parkinson's, Huntington's and ALS.

Eskil Elmer Ph. D., Maas Scientific Director will present the company and also showcase Hawaii as the "Biotech Island" at the Swedish meeting. "The Forum is an ideal venue to reach the key decision makers of some of our target corporations. It is the first Small Biotech/Big Pharma forum in Sweden. Our intellectual property was created in Sweden, and brought to Hawaii. CONNECT takes us back to Sweden to develop alliances with Scandinavian and European corporations. The next step should bring an improved proprietary cyclosporin formulation to clinical trials."

Maas CEO Marcus Keep, M.D reports "In addition to bringing pharmaceutical partners of our own back to Hawaii, we hope to encourage other Swedish biotechs to set up their American division in Hawaii instead of New Jersey or California."

"The timing is good for Maas participation in CONNECT." said Helmuth von Moltke, Maas Corporate Director. "With our receiving the USA patent only 6 days before the forum, there is increased international attention on cyclosporin as THE neuroprotectant. Cyclosporin will likely be the very first clinical drug to actually be effective in humans with stroke, of which there are over 700 000 a year in the USA alone."

Maas Home

© Maas Biolab, Inc. All rights reserved